About this roundup. Ambarish Giliyar is a Bengaluru healthtech marketer-analyst at Jinjr Health, and one of the more prolific curators of healthcare-technology signal on LinkedIn (north of 20,000 followers). Over the week of 14 to 19 September 2026 he published a steady stream of posts spanning India’s healthcare market, sector economics, the AI and frontier-tech megatrends, clinical AI, and the patient and payer experience. We have gathered them here, grouped by theme, with each post embedded so you can read it in full and engage on LinkedIn. Think of it as a week in the life of a healthtech analyst’s feed.
India’s healthcare opportunity and growth
Three of the week’s posts circled the same conviction: India’s healthcare delivery system is both the problem statement and the opportunity. He opened with AI’s role in Indian healthcare delivery.
He then pointed to expansion and high-acuity specialties as the growth engine of the Indian healthcare sector, and separately to the global HealthTech leaderboard where Indian companies such as Ultrahuman, Welcome Cure, DeepTek and Health Basix now feature.
The money and the macro: jobs, funding and risk
If the first thread was opportunity, the second was economics. His most analytical post of the week broke down why the US healthcare sector is the country’s job-growth leader, with national health spending projected past $6 trillion in 2026 and labour costs alone near $2.4 trillion, roughly 40% of the total.
On the capital side, he flagged the HSBC Innovation Banking mid-year report showing healthcare startups raised about $31 billion across 1,101 deals in the first half of 2026, and, more soberly, the key findings of the 2026 Global Risk report.
The AI and frontier-tech megatrends
A large share of the week looked past healthcare to the technology substrate underneath it. He shared framings of the global technology race to 2040, Google’s AI and Economy ATLAS on how AI is reshaping work, the eye-watering scale of data-centre capital expenditure (PwC’s estimate of up to $31.6 trillion through 2050), and the IEEE’s five megatrends for 2030: AI, Energy, Health, Space and Physical AI.
From model to bedside: clinical AI and interoperability
Where the megatrend posts zoomed out, these zoomed back in on the hard part: making AI actually change clinical work. He profiled the emerging radiology-AI marketplace (opportunity, competitive landscape and challenges), argued that an AI-native healthcare system should be judged by whether it transforms clinical workflow rather than by model benchmarks, and shared the OECD’s work on interoperability as the interconnected foundation the rest depends on.
Patients, payers and the long view
The most human post of the week was one he amplified from Ditto, a story about a family in an ambulance frantically trying to work out which hospital would honour a cashless claim, a reminder that network size on paper means nothing at the point of panic. Alongside it he tracked the structural shift in US health insurance toward Alternative Health Plans, and shared a longevity framework separating healthspan from lifespan.
And one for the marketers
He closed the week with a #FridayFunda observation that will resonate with anyone in healthtech go-to-market: when an institution promotes its founder or C-suite more than its solution and the outcomes it delivers, that is a signal worth reading.
The through-line
Read together, the week is a coherent thesis rather than a scrapbook. Ambarish keeps returning to the same loop: India has the demand and a fast-growing delivery sector; the capital and the frontier technology are arriving at scale; but the value only lands if AI changes clinical workflow, systems interoperate, and the patient in the ambulance actually knows which hospital to go to. It is a useful feed to follow if you work anywhere along India’s care continuum.
Signals to take forward
Strip the week down to what it means for anyone building in health technology, and a handful of signals emerge. Read them less as predictions and more as design constraints for your own roadmap and product decisions.
-
Build for the workflow first, the moonshot later. Ambarish’s own India-AI framing put appointment and preclinical triage, OPD and clinical consult, and claims and billing in the “scale now” wave, with diagnostic and operational cases needing more investment to mature. If you are prioritising for the Indian delivery market, the near-term value is in workflow optimisation, not autonomous diagnosis.
-
Follow the labour, because that is where the cost is. With compensation near 40% of a projected $6 trillion US health bill, the durable return sits in the labour-intensive administrative layer: clinical documentation, medical coding, revenue-cycle, and scheduling. A solution that removes clinician and back-office minutes has a clearer business case than one that chases a benchmark.
-
Assume compute and capital stop being the constraint. Data-centre capital expenditure measured in tens of trillions and roughly $31 billion into healthcare startups in a single half-year point the same way: model access and inference will keep getting cheaper and more deployable on-premise. Plan for a world where your moat is data quality, workflow integration and trust, not privileged access to a model.
-
Treat interoperability as the platform, not a feature. The OECD interoperability material and the recurring ABDM and FHIR thread say the same thing: solutions that assume clean, consented, portable data will compound, and those that create another silo will not. Build on the rails from day one rather than bolting them on later.
-
Define success as workflow change, then measure it. The AI-native post is the sharpest editorial line of the week: judge a system by whether clinical workflow is genuinely transformed and whether the AI demonstrably helps, not by leaderboard scores. Write your success metric, and the workflow it must change, before you deploy anything.
-
The last mile is a person, often in a hurry. The ambulance story is the emotional core of the week: a network of 20,000 hospitals on paper is useless if a panicked family cannot find the right one nearby at the moment it matters. Whatever you build, test it against the worst moment your user will have, not the demo.
The meta-signal, courtesy of his marketing note, ties it together: sell the outcome, not the founder. In a market this noisy, the solutions that clearly describe what they change for a patient, a clinician or a payer will outlast the ones selling a personality.
Posts embedded above are public and belong to Ambarish Giliyar; follow and engage with them on LinkedIn. Roundup and signals compiled by HCITExperts.